S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
How O.J. Simpson burned the Ford Bronco into America's collective memory
NASDAQ:AMRS

Amyris (AMRS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.05
$1.17
52-Week Range
N/A
Volume
46.75 million shs
Average Volume
12.59 million shs
Market Capitalization
$18.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.10
AMRS stock logo

About Amyris Stock (NASDAQ:AMRS)

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

AMRS Stock News Headlines

Amyris Receives Court Approval for Restructuring Plan
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Amyris Inc AMRSQ
Gevo's Valentine's Day Massacre
Amyris, Inc. (AMRS) Soars: Stock Up 16.0%
Firm Retention Summary: Amyris
Why Amyris Stock Is Rocketing Higher
AMRS Stock Surges 152% as Amyris Files for Bankruptcy
See More Headlines
Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
4/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Specialty Chemicals
Sub-Industry
Oil & Gas Refining & Marketing
Current Symbol
NASDAQ:AMRS
CUSIP
03236M10
Employees
1,598
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$1.10
High Stock Price Target
$1.50
Low Stock Price Target
$0.65
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-528,510,000.00
Net Margins
-229.12%
Pretax Margin
-235.25%

Debt

Sales & Book Value

Annual Sales
$269.85 million
Book Value
($1.52) per share

Miscellaneous

Free Float
235,299,000
Market Cap
$18.47 million
Optionable
Optionable
Beta
1.19

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


AMRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Amyris stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings
or view top-rated stocks.

What is Amyris' stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Amyris' stock. Their AMRS share price targets range from $0.65 to $1.50. On average, they anticipate the company's stock price to reach $1.10 in the next year.
View analysts price targets for AMRS
or view top-rated stocks among Wall Street analysts.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) issued its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $47.90 million for the quarter, compared to analysts' expectations of $64.21 million. Amyris's quarterly revenue was up 39.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.41) earnings per share.

What ETFs hold Amyris' stock?

ETFs with the largest weight of Amyris (NASDAQ:AMRS) stock in their portfolio include AXS Cannabis ETF (THCX).VegTech Plant-based Innovation & Climate ETF (EATV).

When did Amyris' stock split?

Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is John Melo's approval rating as Amyris' CEO?

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

This page (NASDAQ:AMRS) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners